Non-opioid Pain Treatment Market
Report ID: SQMIG35I2668
Report ID: SQMIG35I2668
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2668 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Non-Opioid Pain Treatment Market size was valued at USD 28.52 Billion in 2024 and is poised to grow from USD 30.55 Billion in 2025 to USD 52.85 Billion by 2033, growing at a CAGR of 7.12% during the forecast period (2026-2033).
Primary driver of the non opioid pain treatment market growth is the urgent need to limit opioid related harm while managing burden of chronic pain, reshaping clinical practice and regulation. The market comprises pharmaceutical products such as NSAIDs, antidepressants, anticonvulsants and topical agents with device therapies including neuromodulation, radiofrequency ablation and modalities. This market is significant because safer, effective pain control reduces morbidity, lowers addiction risk and eases healthcare costs.
As a result pharmaceutical firms accelerate development of targeted neuropathic agents and topical formulations while device makers scale neuromodulation platforms for chronic back pain and post surgical analgesia. Payers respond by creating reimbursement pathways for spinal cord stimulation and digital cognitive behavioral therapy, increasing uptake in hospital systems and outpatient clinics. For example hospitals implementing enhanced recovery after surgery protocols reduce opioid use by combining local anesthetics, regional blocks and non opioid medications, illustrating clear commercial and clinical opportunity.
How is AI advancing personalized therapies in the non-opioid pain treatment market?
AI is enabling personalization in the non-opioid pain treatment market by converting clinical history, wearable signals, imaging and patient reported outcomes into individualized care plans. Key features include the identifying distinct pain profiles, predicting which non opioid therapies will work best for a given person, and continuously adapting treatments as patients respond. The current landscape shows early clinical adoption of AI driven platforms in specialty clinics and digital therapeutic programs, with payers and providers increasingly open to safer alternatives to opioids.
Electrome in March 2026, announced a programmable AI driven bioelectric pain management platform in partnership with BioElectronics Corp that applies machine learning to personalize stimulation and automate titration. This innovation supports market growth by scaling non pharmacologic options, reducing clinician burden, and improving efficiency of delivering tailored pain care.
Market snapshot - (2026-2033)
Global Market Size
USD 28.52 Billion
Largest Segment
NSAIDs
Fastest Growth
Anticonvulsants (Gabapentinoids)
Growth Rate
7.12% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global non-opioid pain treatment market is segmented by drug class, pain type, route, end-user and region. Based on drug class, the market is segmented into NSAIDs, COX-2 Inhibitors, Anticonvulsants (Gabapentinoids), SNRIs and Nerve Blocks. Based on pain type, the market is segmented into Neuropathic Pain, Musculoskeletal Pain, Post-Surgical Pain and Chronic Pain. Based on route, the market is segmented into Oral, Injectable and Topical. Based on end-user, the market is segmented into Hospitals, Pain Clinics and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Gabapentinoids segment dominates with large non-opioid pain treatment market share because their mechanism directly reduces neuronal hyperexcitability central to neuropathic pain, delivering symptom relief that clinicians rely on when opioid therapies are inappropriate. Robust clinical support and guideline endorsements bolster prescriber confidence, while tolerability and ease of dosing favor chronic use. These factors promote formulary inclusion and routine prescribing across care settings, reinforcing sustained market leadership through clinical and payer acceptance.
As per non-opioid pain treatment market outlook, SNRIs have developed into the fastest growing segment because they help relieve both co-occurring pain and depressive symptomatology. Increased clinician knowledge of SNRIs, label acceptance and new formulations driving further adoption will enable their use in combination with different pain management approaches to create new opportunities for market growth. Topical formulations are rapidly affecting the retail pharmacy adoption of non-opioid pain treatments.
As per non-opioid pain treatment market analysis, retail pharmacies segment is the leading source for access to non-opioid analgesics and topical treatments; the combination of a broad consumer base and pharmacist drug counseling to promote self management and conversion of scripts into OTC products contributes to the strong growth in the category. Ongoing partnerships between manufacturers and pharmacies coupled with the ability to support rapid product uptake through clinician interactions will support the continued growth of both the non-opioid and topical formulations.
As per non-opioid pain treatment market forecast, pain clinics are experiencing the strongest growth due to growing number of multi-disciplinary practices adopting multimodal non-opioid protocols and advanced interventions requiring more specialized therapeutics products. With a concentration of clinical expertise in these types of practices, the adoption of new formulations occurs at an increased rate because of direct engagement with payers, which will help to shape additional use cases and treatment pathways and further increase the overall market opportunity.
To get detailed segments analysis, Request a Free Sample Report
The healthcare systems in Canada and the US provide strong support for the emergence of non-opioid analgesia. These systems are comprised of collaborative innovation, both in the area of drug development and drug delivery (manufacturing) and supply networks; there is an increasing focus on public health initiatives that promote access to high-quality healthcare, including non-opioid pain treatments.
As per non-opioid pain treatment market regional forecast, U.S. is characterized by a high degree of clinical innovation, broad-based drug development efforts across a broad spectrum of diseases and conditions, and significant investment in non-opioid analgesia and device-based therapy. Many private payers are increasingly supportive of opioid-sparing options and encourage guidelines that will lead to opioid-sparing practices across both acute and chronic care.
As per non-opioid pain treatment market regional outlook, Canada is largely characterized by high public healthcare engagement, active discussions about policies that will support opioid-sparing strategies and a focus on interdisciplinary approaches to pain management. Thus, the state of health programs supports both the promotion of and access to non-pharmacological and medication alternatives, while also providing reimbursement considerations at the provincial level. These factors collectively promote innovation in research and facilitate the translation of new approaches into clinical practice. Patient-focused efforts are also driving demand for safer pain management strategies, thereby informing the development of evidence-based national practice guidelines among specialists.
As per non-opioid pain treatment industry analysis, rapid, collective action is driving the development of non-opioid therapeutic alternatives to pain management across Europe. This growth is made possible through the simultaneous implementation of coordinated national policies, a burgeoning focus on multidisciplinary approaches to care, and a strong and sustained supply of non-opioid therapies from joint development efforts. Health technology assessment (HTA) processes and new clinical guidelines are favoring the adoption of non-opioid alternatives by clinicians. Additionally, specialist societies that share knowledge between countries through an organized exchange of information and integrated care programs are accelerating the dissemination of best practice models across Europe. Ongoing investment in digital health technologies and rehabilitation modalities (therapies) are also enhancing the overall pharmacologic innovation within the non-opioid treatment sector. Industry partners and public research institutions are enhancing their collaborative engagement in the localization of new non-opioid therapies within each of their respective national markets. Both diverse payer models and patient advocacy/create demand for increased market access, while collaborative research and development organizations are accelerating the availability of new non-opioid therapies to the market by way of strategic partnerships between industry and academia.
Germany has built a comprehensive non-opioid pain treatment market on a foundation of strong clinical research capabilities, well-established specialist networks, and the proactive incorporation of multimodal approaches to pain management within its hospital systems. The reimbursement structure and clinical practice guideline committees encourage the use of non-opioids as first-line therapies for pain management within acute and chronic care settings, providing the necessary incentive for clinicians to use these products. The collaborative relationship between academic institutions and developers of medical devices promotes the introduction of new minimally invasive products into the marketplace. Patient awareness campaigns and rehabilitation services are also helping to stimulate the demand for non-opioid interventions along all care delivery pathways.
Non-opioid Pain Treatment Market in United Kingdom is defined by adoption of opioid-sparing protocols, strong primary care engagement and clinical education efforts. Rapid guideline updates and commissioning frameworks encourage integration of alternative analgesics and non-pharmacologic therapies into routine practice. A thriving ecosystem of health technology innovators and digital therapeutics developers supports solutions for pain management. Patient advocacy and multidisciplinary clinics enhance referral pathways and increase clinician confidence prescribing non-opioid options.
France is emerging through strengthened clinical guidelines, investment in rehabilitation services and growing interest in non-pharmacologic modalities. Regional centers of excellence and hospital networks integrate alternative analgesics and device-based therapies into standard pathways. Public discussions about safer pain management and pilot programs build clinician familiarity and patient demand. Collaborations between research institutions and commercial partners support translation of novel approaches into practice across regional systems.
Asia-Pacific region is increasing its contribution towards non-opioid options by expanding clinical research capacity; developing local manufacturing of products; and actively pursuing the introduction of innovative therapies that are customized to meet the specific clinical needs of different regions. This increase in development and implementation of medical devices, digital health platforms and rehabilitation services will complement the overall pharmaceutical development and will create more integrated models of pain management. Regulatory authorities are working with the use of international standards so that countries can collaborate on research, cross-border collaboration, and clinical studies.
Japan non-opioid pain treatment market is supported by a mature health system which has established itself through having an extensive amount of medical research, advanced manufacturing capabilities for medical devices, and an integrated multi-modal health system to provide pain management in the hospitals. Regulatory engagement is very supportive of the adoption of evidence-based medicine from international sources, while Japanese companies are focused on innovating their own research and development around minimally invasive devices and better ways to formulate medications. Continuing education and rehabilitation services for health professionals increase the number of health professionals who can implement opioid-sparing protocols.
South Korea is progressing through innovative clinical research and developing rapid regulatory review processes for Med Tech products companies as well as creating a Med Tech sector that specializes in minimally invasive therapies for patients. There is an increasing number of hospitals implementing device-based interventions for patients, and combining them with rehabilitation services and digital tools helps to implement a more comprehensive approach to pain management. There is a growing number of current collaboration and public-private partnerships to continue to develop and localise alternative therapies to opioids. There are also increasing numbers of continuing education opportunities for health professionals and patient education initiatives to increase the acceptance of opioid-sparing options in the different care settings and regions.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Demand For Nonopioid Therapies
Advancements In Drug Delivery Technologies
Regulatory Complexity and Variability
Reimbursement Challenges and Coverage
Request Free Customization of this report to help us to meet your business objectives.
Consolidation and strategic partnerships are growing as more companies seek out opioid alternatives. Various forms of acquisition and partnership have been done to create differentiated assets or to acquire a proprietary ion channel or biologics platform. Examples include the acquisition of Relievant Medsystems by Boston Scientific; collaborations between Vertex Pharmaceuticals and other biotech companies on sodium channel inhibitors; and the work of numerous smaller companies that are advancing new ion channel inhibitors and TAFA4 peptide biologics that target pain in new ways through differentiation in their mechanisms.
Johnson & Johnson MedTech in July 2025 made a strategic co-promotion agreement with Pacira BioSciences to bring together both their capabilities such as overall orthopaedic knowledge base from J&J's success and non-opioid injectable products; ultimately providing professionals' better education in addition to using more advanced technology through extended release non-operativeways to manage pain.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global non-opioid pain treatment market growth is being driven by the urgent need to limit opioid-related harm and, additionally, by advancements in drug delivery technologies that improve targeting and tolerability. Regulatory complexity and variability remain a key restraint, slowing approvals and market access. North America continues to dominate given its mature healthcare infrastructure, strong research networks and supportive reimbursement pathways. Within therapeutic classes, gabapentinoids lead market share due to robust clinical evidence and guideline support for neuropathic pain. Growing adoption of digital therapeutics and neuromodulation solutions amplifies commercial opportunities across hospitals and outpatient clinics.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 28.52 Billion |
| Market size value in 2033 | USD 52.85 Billion |
| Growth Rate | 7.12% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Non-opioid Pain Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Non-opioid Pain Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Non-opioid Pain Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Non-opioid Pain Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Non-Opioid Pain Treatment Market size was valued at USD 28.52 Billion in 2024 and is poised to grow from USD 30.55 Billion in 2025 to USD 52.85 Billion by 2033, growing at a CAGR of 7.12% during the forecast period (2026-2033).
Competitive landscape shows rapid consolidation and targeted collaborations driven by demand for opioid alternatives, with M&A used to secure differentiated device assets and licensing, and partnerships to access ion channel and biologic platforms. Examples include Boston Scientific’s acquisition of Relievant Medsystems. Vertex and biotech collaborations on sodium channel inhibitors illustrate strategic licensing and co development moves. Startups are advancing Nav channel inhibitors and TAFA4 peptide biologics as mechanism differentiated alternatives. 'Pfizer Inc. (Lyrica)', 'Eli Lilly (Cymbalta)', 'Johnson & Johnson', 'AbbVie (Cerevel)', 'Averitas Pharma', 'Tonix Pharmaceuticals', 'Vertex Pharmaceuticals', 'Trevena Inc.', 'Centrexion Therapeutics', 'Heron Therapeutics', 'Pacira BioSciences', 'Adynxx Inc.', 'Epigenomics AG', 'Grunenthal GmbH', 'Assertio Therapeutics', 'Zyla Life Sciences', 'Sumitomo Pharma', 'Samuels-Pennington', 'Eliem Therapeutics', 'Aevi Technologies'
The growing patient preference for non-opioid pain management over opioid alternatives, driven by concerns about dependency and adverse effects, encourages healthcare providers and payers to incorporate alternative therapies into treatment pathways. This preference motivates pharmaceutical and device manufacturers to expand research, diversify product portfolios, and pursue regulatory approvals for novel non-opioid options. Increased clinical adoption across care settings reinforces market visibility and payer support, facilitating broader distribution and commercialization efforts that collectively stimulate sustained market expansion and investment in the sector.
Precision And Personalized Therapies: Increasing emphasis on patient stratification and biomarker driven approaches is reshaping product development and market positioning in non opioid pain management. Stakeholders are prioritizing tailored formulations, targeted delivery mechanisms, and individualized care pathways to improve outcomes and adherence. Collaboration between specialty clinics, diagnostics providers, and pharmaceutical innovators enables differentiated value propositions and premium positioning. Market entrants focus on niche segments and patient centric services to build sustained engagement and therapeutic relationships and commercial scalability.
Why does North America Dominate the Global Non-opioid Pain Treatment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
